USSTOCK.TODAY
Pre-Market
Log in Sign up

AbbVie signs $757 million licensing deal with Bryce Pharma for migraine treatment

Pharmaceutical Technology · ·by G4L

ABBV Abbvie Inc
$293.30 +0.68%
View chart & analysis →
  1. 1AbbVie announced a licensing agreement with Bryce Pharma for two preclinical-stage migraine programs.
  2. 2AbbVie's development, commercialization, regulatory, and sales milestone costs total up to $757 million.
  3. 367 ongoing clinical trials evaluating migraine treatments have been identified.

So what's the key point?

AbbVie has signed a deal with Bryce Pharma to develop a migraine treatment. The plan involves spending up to $757 million to create a new medicine.

Source Pharmaceutical Technology · View original ↗

Related 3-line summaries

Allergan Aesthetics Announces Phase 4 Clinical Study Results for Adults Taking GLP-1 InvestorsHub +1 · 13h agoAbbVie confirms efficacy of combination therapy in Phase 2 trial of Crohn's disease treatment ABBV-466 The Motley Fool +1 · Nov 2AbbVie reports third-quarter results beating estimates and announces dividend increase The Motley Fool +1 · Oct 31
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news